Eisai R&d Management Co., Ltd.

Yasuhiro Zaima

Margaret Moline

Gina Pastino

Yurie Akimoto

Nobuya Suzuki

Nobuo Yoshida

Yosuke Ueki

Kanta Horie

Shuntaro Arase

Kentaro Nagane

Kazuo Kazama

In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.

Compositions and methods for treating insomnia

The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d] [1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.

Pharmaceutical composition of fused aminodihydrothiazine derivative

Growing community of inventors

Kakamigahara, Japan

Yasuhiro Zaima